The Effect of the Prosthetic Group on the Pharmacologic Properties of 18 F-labeled Rhodamine B, a Potential Myocardial Perfusion Agent for PET
暂无分享,去创建一个
S. Treves | M. Bartholomä | F. Fahey | A. Packard | Amanda Baker | V. Gottumukkala | P. Dunning | Shaohui Zhang
[1] D. Dey,et al. Automatic 3D registration of dynamic stress and rest (82)Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction. , 2011, Medical physics.
[2] M. Phelps,et al. Phase I, First-in-Human Study of BMS747158, a Novel 18F-Labeled Tracer for Myocardial Perfusion PET: Dosimetry, Biodistribution, Safety, and Imaging Characteristics After a Single Injection at Rest , 2011, The Journal of Nuclear Medicine.
[3] S. Nekolla,et al. The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. , 2011, Seminars in nuclear medicine.
[4] A. Fischman,et al. Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium Ion. A Potential Myocardial Blood Flow Agent for PET , 2011, Molecular Imaging and Biology.
[5] S. Nekolla,et al. Simplified Quantification of Myocardial Flow Reserve with flurpiridaz F 18: Validation with Microspheres in a Pig Model , 2011, The Journal of Nuclear Medicine.
[6] D. Berman,et al. Development of a method for the determination of dose ratio and minimum inter-injection interval for a one-day rest-stress protocol with BMS747158 PET myocardial perfusion agent , 2010 .
[7] S. Treves,et al. Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent. , 2010, Nuclear medicine and biology.
[8] S. Robinson,et al. Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[9] Xianzhong Zhang,et al. Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography. , 2010, Bioorganic & medicinal chemistry.
[10] B. Långström,et al. Synthesis and in vitro evaluation of 18F-labelled di- and tri(ethylene glycol) metomidate esters , 2009 .
[11] G. Beller,et al. A welcomed new myocardial perfusion imaging agent for positron emission tomography. , 2009, Circulation.
[12] B. Långström,et al. (18)F-labelled metomidate analogues as adrenocortical imaging agents. , 2009, Nuclear medicine and biology.
[13] X. Shao,et al. Fluorine‐18 Radiopharmaceuticals , 2009 .
[14] Lisheng Cai,et al. Chemistry with [18F]Fluoride Ion , 2008 .
[15] F. Bengel,et al. Cardiovascular nuclear imaging: from perfusion to molecular function , 2008, Heart.
[16] S. Robinson,et al. Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers. , 2008, Journal of medicinal chemistry.
[17] S. Nekolla,et al. Initial Characterization of an 18F-Labeled Myocardial Perfusion Tracer , 2008, Journal of Nuclear Medicine.
[18] Mary Guaraldi,et al. BMS-747 158-02: A novel PET myocardial perfusion imaging agent , 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[19] S. Robinson,et al. Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes: a novel PET myocardial imaging agent , 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[20] L. Becker,et al. Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin , 2007, Journal of Nuclear Medicine.
[21] Daniel S. Berman,et al. Myocardial perfusion and function: Single photon emission computed tomography , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[22] R. Dannals,et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] E. Novellino,et al. Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. , 2005, Journal of medicinal chemistry.
[24] B. Abraham,et al. Photophysical, Photochemical, and Tumor-selectivity Properties of Bromine Derivatives of Rhodamine-123 , 2005, Photochemistry and photobiology.
[25] Y. Zea‐Ponce,et al. Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. , 2005, Bioorganic & medicinal chemistry.
[26] R. Huesman,et al. Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] R. Dannals,et al. Radiosynthesis of 3-[18F]fluoropropyl and 4-[ 18F]fluorobenzyl triarylphosphonium ions , 2004 .
[28] M. Komiyama,et al. Predominant role of basicity of leaving group in α-effect for nucleophilic ester cleavage , 2004 .
[29] Paiboon Reungpatthanaphong,et al. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. , 2003, Journal of biochemical and biophysical methods.
[30] A. Studenov,et al. Synthesis and properties of 18F-labeled potential myocardial blood flow tracers. , 2001, Nuclear medicine and biology.
[31] M. Nascimento,et al. Ab Initio Calculations of Absolute pKa Values in Aqueous Solution II. Aliphatic Alcohols, Thiols, and Halogenated Carboxylic Acids , 2000 .
[32] M. Goodman,et al. Synthesis and evaluation of a new fluorine-18 labeled rotenoid as a potential PET probe of mitochondrial complex I activity , 1999 .
[33] F. Speleman,et al. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein , 1999, European Journal of Nuclear Medicine.
[34] Alun G. Jones,et al. Interspecies variation in biodistribution of technetium (2-carbomethoxy-2-isocyanopropane)6+. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] M. Dhalla,et al. In vivo studies of unlabeled and radioiodinated rhodamine-123. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[36] B. Holman,et al. Comparison of neutral and cationic myocardial perfusion agents: characteristics of accumulation in cultured cells. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[37] I. L. Arbeloa,et al. Dimeric states of rhodamine B , 1982 .
[38] F. Fahey,et al. Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[39] A. Składanowski,et al. Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. , 2008, Acta biochimica Polonica.
[40] S. Robinson,et al. Assessment of 18F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[41] H. Coenen. Fluorine-18 labeling methods: Features and possibilities of basic reactions. , 2007, Ernst Schering Research Foundation workshop.
[42] Josef Machac,et al. Cardiac positron emission tomography imaging. , 2005, Seminars in nuclear medicine.
[43] C. Crouzel,et al. Chemistry of β +-Emitting Compounds Based on Fluorine-18 , 2002 .
[44] N. Savaraj,et al. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. , 2000, Biochemical pharmacology.
[45] B. Sobel,et al. Cardiac Positron Emission Tomography , 1996, Developments in Cardiovascular Medicine.
[46] W. L. Mock,et al. Concerning the relative acidities of simple alcohols , 1990 .
[47] T. Lampidis,et al. Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. , 1985, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.